Predictors of Epicardial Fat Volume Decrease after Dapagliflozin Treatment in Patients with Type 2 Diabetes

Background and Objectives: Dapagliflozin treatment proved to reduce the epicardial fat volume (EFV) in patients with type 2 diabetes (T2D). Despite the reduction in EFV being associated with improved diastolic function in patients with T2D, EVF is not routinely evaluated in T2D because it is costly...

Descripción completa

Detalles Bibliográficos
Autores principales: Braha, Adina, Albai, Alin, Timar, Bogdan, Cipu, Daniela, Vasiluță, Lucian, Potre, Ovidiu, Timar, Romulus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777745/
https://www.ncbi.nlm.nih.gov/pubmed/35056329
http://dx.doi.org/10.3390/medicina58010021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777745/
https://www.ncbi.nlm.nih.gov/pubmed/35056329
http://dx.doi.org/10.3390/medicina58010021

Ejemplares similares